Chen Zihan, Cheng Zaihua, Ding Congcong, Cao Tianyu, Chen Ling, Wang Hong, Li Junpei, Huang Xiao
Department of Cardiology, the Second Affiliated Hospital of Nanchang University, Nanchang, China.
Queen Mary School, Medical Department, Nanchang University, Nanchang, China.
Cardiovasc Drugs Ther. 2025 Jun;39(3):615-631. doi: 10.1007/s10557-023-07531-3. Epub 2023 Dec 18.
The transient receptor potential melastatin 2 (TRPM2) channel is a nonselective calcium channel that is sensitive to oxidative stress (OS), and is widely expressed in multiple organs, such as the heart, kidney, and brain, which is inextricably related to calcium dyshomeostasis and downstream pathological events. Due to the increasing global burden of kidney or cardiovascular diseases (CVDs), safe and efficient drugs specific to novel targets are imperatively needed. Notably, investigation of the possibility to regard the TRPM2 channel as a new therapeutic target in ROS-related CVDs or renal diseases is urgently required because the roles of the TRPM2 channel in heart or kidney diseases have not received enough attention and thus have not been fully elaborated. Therefore, we aimed to review the involvement of the TRPM2 channel in cardiovascular disorders related to kidney or typical renal diseases and attempted to speculate about TRPM2-mediated mechanisms of cardiorenal syndrome (CRS) to provide representative perspectives for future research about novel and effective therapeutic strategies.
瞬时受体电位M型2(TRPM2)通道是一种对氧化应激(OS)敏感的非选择性钙通道,广泛表达于心脏、肾脏和大脑等多个器官,与钙稳态失衡及下游病理事件密切相关。由于全球肾脏或心血管疾病(CVD)负担日益加重,迫切需要针对新靶点的安全有效的药物。值得注意的是,由于TRPM2通道在心脏或肾脏疾病中的作用尚未得到足够重视,也未得到充分阐述,因此迫切需要研究将TRPM2通道作为ROS相关CVD或肾脏疾病新治疗靶点的可能性。因此,我们旨在综述TRPM2通道在与肾脏相关的心血管疾病或典型肾脏疾病中的作用,并试图推测TRPM2介导的心肾综合征(CRS)机制,为未来新型有效治疗策略的研究提供有代表性的观点。